Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: …

Written By Carla Aguilera

…A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.

Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D.

Cancer. 2022 Nov 1;128(21):3775-3783. doi: 10.1002/cncr.34445. Epub 2022 Sep 13. PMID: 36101004

Carla Aguilera
Previous

Overcoming inter-observer planning variability in target volume contouring and dose planning …
Next

Presenting features of neuroblastoma with spinal canal invasion. A prospective study of … (SIOPEN)